Camidanlumab tesirine
Based on 1 Customer Validation
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines.
For research use only. We do not sell to patients.
- CAS No.: 1853239-04-9
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Camidanlumab tesirine (ADCT 301; 3, 10 ng/mL; 48 hours) resultes in a dose-dependent G2-M arrest reaching a maximum at 48 hours[1].
Camidanlumab tesirine (10 ng/mL; 24-96 hours) induces apoptosis[1].
Camidanlumab tesirine has the GI50 values ranged from 0.04-2.94 ng/mL in the CD25-positive lines. GI50 values in the CD25-negative lines are >1,000 ng/mL. The nonbinding ADC gives GI50 values >1,000 ng/mL in both antigen-expressing and nonexpressing lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Karpas 299 cell
-
Concentration:3, 10 ng/mL
-
Incubation Time:48 hours
-
Result:Resulted in a dose-dependent G2-M arrest reaching a maximum at 48 hours as evidenced by a decreased percentage of cells in G0-G1 and an increased percentage in G2-M compared with untreated control.
-
Cell Line:Karpas 299 cell
-
Concentration:10 ng/mL
-
Incubation Time:24, 48, 60, 72 and 96 hours
-
Result:The peak of the early apoptosis marker Annexin-V on the cell surface of Karpas 299 cells was observed between 60 and 72 hours.
Camidanlumab tesirine has the half-life of 7.3 days by analysis of the conjugated antibody with DAR component ≥1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6- to 8-week-old female Fox Chase SCID mice subcutaneous CD25-expressing Karpas 299 cells[1]
-
Dosage:0.1, 0.2, 0.4, 0.6 mg/kg
-
Administration:IV; daily; 60 days
-
Result:Delayed tumor growth in a dose-dependent fashion with the 0.6 mg/kg cohort demonstrating 10 of 10 tumor-free survivors at day 60.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1853239-04-9
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Camidanlumab tesirine]
-
Synonyms
ADCT 301
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Michael J Flynn, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther. 2016 Nov;15(11):2709-2721. [Content Brief]
[2]. Francesca Zammarchi, et al. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020 Sep;8(2):e000860. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Camidanlumab tesirine Related Classifications
HY-141599 Related Classifications
Powered by Bioz